Merck unveils Phase 3 data for BELSOMRA C-IV in treatment of insomnia
Category: #headlines  By Mateen Dalal  Date: 2019-05-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck unveils Phase 3 data for BELSOMRA C-IV in treatment of insomnia

It is the first dedicated Phase 3 polysomnography study for the treatment of insomnia in people having mild-to-average Alzheimer’s disease and dementia

Pharmaceutical company Merck, also known as MSD outside Canada and the United States, has recently presented the Phase 3 trial results for evaluation of the safety and efficacy of BELSOMRA (suvorexant) C-IV for treating insomnia in individuals with mild to average Alzheimer’s disease dementia.

Sources familiar with the matter informed that this presentation is the first dedicated Phase 3 polysomnography study for the treatment of insomnia in people having mild-to-average Alzheimer’s disease and dementia. In the trial run, BELSOMRA achieved its primary and secondary efficacy endpoints.

Reportedly, in case of primary endpoint, 4-weeks of treatment with BELSOMRA improved average total sleep time by 28.2 minutes. This corresponded to a mean increase from baseline of 45.2 minutes with placebo and a mean increase from baseline of 73.4 minutes with BELSOMRA. Adverse events were reported in 16.1% of patients receiving placebo compared to 22.5% of those receiving BELSOMRA.

Seemingly, the presentation results are being presented at the 2019 Annual Meeting of American Academy of Neurology, held between May 4 to 10 in Philadelphia, PA.

According to associate vice president of Global Clinical Research, Neuroscience, Merck Research Laboratories, Dr. W. Joseph Herring, insomnia and other kind of sleep disturbances are very common in people with Alzheimer’s disease dementia.

Dr. Herring said evidence for the safety and efficacy of sleep medications in this population remains restricted. Merck aims to file these data with the USFDA, (United States Food and Drug Administration) for potentially including in the BELSOMRA prescribing info.

BELSOMRA C-IV 20 mg,15 mg,10 mg, 5 mg tablets are presently approved by the USFDA for the treatment of insomnia in people who are struggling with sleep maintenance and sleep onset, sources added. The Phase 3 trial comprised of a 3-week screening period along with a 2-week single blind placebo run and was also followed by a 4-week double blind randomized treatment phase.

 

Source Credit: https://www.streetinsider.com/Corporate+News/Mercks+%28MRK%29+BELSOMRA+C-IV+Meets+Primary+Efficacy+Endpoint+in+Phase+3+Trial+for+Treatment+of+Insomnia+in+People+with+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease+Dementia/15461085.html

https://www.mrknewsroom.com/news-release/research-and-development-news/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-en

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Health insurer Alan acquires Jour to enter the mental health market
Health insurer Alan acquires Jour to enter the mental health market
By Mateen Dalal

Alan, a health insurance startup based in France, has acquired American digital behavioral health firm, Jour for $20 million. The acquisition has assisted the French health insurer to launch its new digital health service, Alan Mind, helping it ...

WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
By Mateen Dalal

South Korean consumer equipment firm, WAVE Electronics has recently formed an alliance with home automation company, Savant Systems, Inc. to provide CYNC™ smart home solutions to its contractors, custom installation professionals, and builders ...

WardWizard Innovations & Mobility to invest $20Mn in EV business
WardWizard Innovations & Mobility to invest $20Mn in EV business
By Mateen Dalal

Indian electric vehicle manufacturer, WardWizard Innovations and Mobility have expressed plans to spend INR 150 crore (USD 20 million) in the coming six months in its EV business, as it seeks to ramp up technology and infrastructure, among other thin...